New and amended listings on the Pharmaceutical Benefits Scheme (PBS), the Repatriation Pharmaceutical Benefits Scheme, the Life Saving Drugs Program, the National Epidermolysis Bullosa Dressing Scheme and the Stoma Appliance Scheme.
The Government will provide $2.2 billion over 5 years from 2022-23 for new and amended listings on the Pharmaceutical Benefits Scheme (PBS), the Repatriation Pharmaceutical Benefits Scheme, the Life Saving Drugs Program, the National Epidermolysis Bullosa Dressing Scheme and the Stoma Appliance Scheme. Examples of new and amended PBS listings since the 2022-23 October Budget include:
* nirmatrelvir and ritonavir (Paxlovid), for the treatment of adults with COVID-19
* evolocumab (Repatha) from 1 December 2022, for the treatment of hypercholesterolaemia
* pegcetacoplan (EMPAVELI) from 1 December 2022, for the treatment of adults with paroxysmal nocturnal haemoglobinuria
* vericiguat (Verquvo) from 1 December 2022, for the treatment of chronic heart failure
* daratumumab (Darzalex) from 1 January 2023, for the treatment of newly diagnosed systemic light chain amyloidosis
* faricimab (Vabysmo) from 1 January 2023, for the treatment of neovascular age-related macular degeneration and diabetic macular oedema
* nivolumab + ipilimumab (OPDIVO/YERVOY) from 1 March 2023, for the treatment of Stage III or IV malignant melanoma
* elexacaftor + tezacaftor + ivacaftor (Trikafta) from 1 May 2023, for the treatment of cystic fibrosis in patients aged 6 to 11 years
* vosoritide (Voxzogo) from 1 May 2023, for the treatment of patients with achondroplasia whose epiphyses are not closed. The cost of some medicines listed will be reduced by revenue from rebates negotiated as part of purchase agreements. Details of the receipts for this measure are not for publication (nfp) due to commercial sensitivities. Health and Aged Care |